➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Colorcon
Moodys
Harvard Business School
Dow

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RAMUCIRUMAB

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Biosimilar Clinical Trials for ramucirumab

This table shows clinical trials for biosimilars. See the next table for all clinical trials
Trial ID Title Status Sponsor Phase Start Date Summary
NCT03766607 ↗ Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Not yet recruiting Korean South West Oncology Group Phase 2 2019-01-31 The aim of this study is to evaluate the efficacy and safety of combination therapy with ramucirumab, paclitaxel, and trastuzumab biosimilar as second line treatment of HER2 positive metastatic gastric cancer after failure of first line chemotherapy including trastuzumab. This study is a phase II, single-arm, open label, multi-center study.
>Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for ramucirumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00533702 ↗ A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma Completed Eli Lilly and Company Phase 2 2007-11-01 The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine.
NCT00683475 ↗ A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer Completed Eli Lilly and Company Phase 2 2008-08-01 The purpose of this study is to determine whether IMC-A12 or IMC-1121B (ramucirumab) with Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent prostate cancer (APIC).
NCT00703326 ↗ Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer Active, not recruiting Eli Lilly and Company Phase 3 2008-08-01 The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ramucirumab

Condition Name

Condition Name for ramucirumab
Intervention Trials
Gastric Cancer 17
Gastroesophageal Junction Adenocarcinoma 14
Gastric Adenocarcinoma 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ramucirumab
Intervention Trials
Adenocarcinoma 37
Stomach Neoplasms 27
Esophageal Neoplasms 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ramucirumab

Trials by Country

Trials by Country for ramucirumab
Location Trials
United States 560
Canada 33
United Kingdom 32
Spain 28
Australia 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ramucirumab
Location Trials
Texas 30
California 30
New York 29
Tennessee 26
Florida 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ramucirumab

Clinical Trial Phase

Clinical Trial Phase for ramucirumab
Clinical Trial Phase Trials
Phase 3 14
Phase 2/Phase 3 2
Phase 2 64
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ramucirumab
Clinical Trial Phase Trials
Not yet recruiting 49
Recruiting 37
Completed 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ramucirumab

Sponsor Name

Sponsor Name for ramucirumab
Sponsor Trials
Eli Lilly and Company 66
National Cancer Institute (NCI) 10
Merck Sharp & Dohme Corp. 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ramucirumab
Sponsor Trials
Industry 102
Other 55
NIH 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
McKesson
Colorcon
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.